Traders Sell Shares of Becton, Dickinson and Company (BDX) on Strength Following Insider Selling

Traders sold shares of Becton, Dickinson and Company (NYSE:BDX) on strength during trading on Monday after an insider sold shares in the company. $49.13 million flowed into the stock on the tick-up and $92.02 million flowed out of the stock on the tick-down, for a money net flow of $42.89 million out of the stock. Of all stocks tracked, Becton, Dickinson and had the 0th highest net out-flow for the day. Becton, Dickinson and traded up $0.17 for the day and closed at $203.87Specifically, insider Gary M. Cohen sold 15,512 shares of Becton, Dickinson and stock in a transaction that occurred on Monday, September 11th. The shares were sold at an average price of $203.77, for a total value of $3,160,880.24. Following the transaction, the insider now owns 95,781 shares in the company, valued at $19,517,294.37. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider Thomas E. Polen, Jr. sold 5,971 shares of Becton, Dickinson and stock in a transaction that occurred on Wednesday, August 9th. The stock was sold at an average price of $197.41, for a total transaction of $1,178,735.11. Following the completion of the transaction, the insider now owns 12,861 shares in the company, valued at approximately $2,538,890.01. The disclosure for this sale can be found here. In the last 90 days, insiders sold 75,904 shares of company stock worth $15,242,688. 1.40% of the stock is currently owned by company insiders.

BDX has been the topic of several recent research reports. Raymond James Financial, Inc. upgraded shares of Becton, Dickinson and from an “outperform” rating to a “strong-buy” rating and decreased their price target for the stock from $210.00 to $180.00 in a research report on Friday, June 30th. Cowen and Company restated an “outperform” rating and issued a $230.00 price target (up previously from $200.00) on shares of Becton, Dickinson and in a research report on Monday, July 10th. BidaskClub upgraded shares of Becton, Dickinson and from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, July 11th. Zacks Investment Research upgraded shares of Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $225.00 price target on the stock in a research report on Monday, July 17th. Finally, Bank of America Corporation restated a “buy” rating and issued a $225.00 price target (up previously from $200.00) on shares of Becton, Dickinson and in a research report on Friday, July 21st. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company. Becton, Dickinson and has a consensus rating of “Buy” and an average price target of $196.93.

The company has a market capitalization of $46.01 billion, a P/E ratio of 58.56 and a beta of 1.06. The stock’s 50 day moving average price is $200.08 and its 200 day moving average price is $191.02.

Becton, Dickinson and (NYSE:BDX) last issued its earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.44 by $0.02. Becton, Dickinson and had a net margin of 6.25% and a return on equity of 22.53%. The firm had revenue of $3.04 billion during the quarter, compared to the consensus estimate of $3.06 billion. During the same quarter in the prior year, the firm earned $2.35 earnings per share. The business’s quarterly revenue was down 5.1% on a year-over-year basis. On average, equities research analysts expect that Becton, Dickinson and Company will post $9.46 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Friday, September 29th. Shareholders of record on Friday, September 8th will be paid a $0.73 dividend. This represents a $2.92 annualized dividend and a yield of 1.44%. The ex-dividend date of this dividend is Thursday, September 7th. Becton, Dickinson and’s payout ratio is presently 83.43%.

Institutional investors have recently added to or reduced their stakes in the company. North Star Investment Management Corp. boosted its holdings in shares of Becton, Dickinson and by 3.4% in the first quarter. North Star Investment Management Corp. now owns 549 shares of the medical instruments supplier’s stock valued at $101,000 after buying an additional 18 shares during the period. Almanack Investment Partners LLC. acquired a new position in shares of Becton, Dickinson and in the first quarter valued at approximately $105,000. Parkside Financial Bank & Trust boosted its holdings in shares of Becton, Dickinson and by 1.4% in the first quarter. Parkside Financial Bank & Trust now owns 633 shares of the medical instruments supplier’s stock valued at $116,000 after buying an additional 9 shares during the period. QCI Asset Management Inc. NY boosted its holdings in shares of Becton, Dickinson and by 9.2% in the first quarter. QCI Asset Management Inc. NY now owns 710 shares of the medical instruments supplier’s stock valued at $130,000 after buying an additional 60 shares during the period. Finally, Mitsubishi UFJ Securities Holdings Co. Ltd. boosted its holdings in shares of Becton, Dickinson and by 55.8% in the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 670 shares of the medical instruments supplier’s stock valued at $131,000 after buying an additional 240 shares during the period. Institutional investors own 87.43% of the company’s stock.

WARNING: “Traders Sell Shares of Becton, Dickinson and Company (BDX) on Strength Following Insider Selling” was originally published by Markets Daily and is the sole property of of Markets Daily. If you are accessing this article on another website, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The original version of this article can be read at https://www.themarketsdaily.com/2017/09/13/traders-sell-shares-of-becton-dickinson-and-company-bdx-on-strength-following-insider-selling.html.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply